Johnson & Johnson reports Phase 3 ICONIC-TOTAL data
Two-year ICOTYDE data from the Phase 3 ICONIC-TOTAL study showed site-specific complete skin clearance at Week 112 in difficult psoriasis sites, including 60% for scalp psoriasis and 89% for genital psoriasis.